VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ORKA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ORKAOruka Therapeutics, Inc.
$96.32$5.8B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksORKAFinancials

Oruka Therapeutics, Inc. (ORKA) Income Statement

21Y historyFree accessUpdated daily

With no revenue recorded across the ten quarters and R&D reaching $53.7M in 2026Q3 against an operating loss of $62.1M, the income statement offers no margin baseline and reflects a clinical-stage cost structure dominated by research spend.

Income StatementBalance SheetCash FlowRatios

ORKA Income Statement

Annual statement

ORKA Income Statement

Oruka Therapeutics, Inc. (ORKA) annual income statement — 21-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05
Sales/Revenue000000000000000000046.86M3.89M545K
Revenue Growth %-------------------100%1105.27%613.39%-
Cost of Goods Sold163K83K27K111K114K91K93K89K22K27K24K19K12K26K43K2.92M338K002.34M3.18M57.78M
COGS % of Revenue-------------------5%81.84%10601.47%
Gross Profit-163K-83K-27K-111K-114K-91K-93K-89K-22K-27K-24K-19K-12K-26K-43K-2.92M-338K0044.52M706K-57.23M
Gross Margin %-------------------95%18.16%-10501.47%
Gross Profit Growth %--207.41%75.68%2.63%-25.27%2.15%-4.49%-304.55%18.52%-12.5%-26.32%-58.33%53.85%39.53%98.53%-763.02%---100%6205.67%101.23%-
Operating Expenses182.94M121.97M88.1M7.18M9.73M19.24M9.67M5.72M8.1M18.68M16.59M11.44M9.68M6.91M4.28M4.44M8.84M22.39M19.27M61.07M141.28M15.8M
OpEx % of Revenue-------------------130.33%3633.74%2900%
Selling, General & Admin29.26M21.33M13.04M6.17M5.26M5.41M4.68M3.89M3.86M4.61M4.24M4.37M4.06M3.99M3.18M4.44M5.73M12.38M8.25M18.42M27.45M15.8M
SG&A % of Revenue-------------------39.31%706.02%2900%
Research & Development153.74M100.64M75.06M1.01M4.46M13.83M4.99M1.83M4.24M14.08M12.35M7.06M5.63M2.93M1.09M03.11M10.01M11.03M42.65M89.37M0
R&D % of Revenue-------------------91.02%2298.61%-
Other Operating Expenses-49K000000000000000000024.46M0
Operating Income-183.11M-122.05M-88.12M-7.3M-9.84M-19.34M-9.77M-5.81M-8.12M-18.71M-16.61M-11.46M-9.69M-6.94M-4.32M-7.36M-9.18M-22.85M-19.49M-16.55M-140.57M-73.04M
Operating Margin %--------------------35.33%-3615.59%-13401.47%
Operating Income Growth %--38.5%-1107.83%25.86%49.1%-97.98%-67.97%28.38%56.62%-12.63%-45.03%-18.18%-39.67%-60.69%41.33%19.77%59.85%-17.22%-17.75%88.22%-92.47%-
EBITDA-182.94M-121.97M-88.1M-7.18M-9.73M-19.24M-9.67M-5.72M-8.1M-18.68M-16.59M-11.44M-9.68M-6.91M-4.28M-6.76M-8.84M-22.39M-19.27M-14.21M-137.39M-70.37M
EBITDA Margin %--------------------30.33%-3533.74%-12911.93%
EBITDA Growth %-45.34%-38.45%-1126.11%26.13%49.45%-98.95%-68.96%29.29%56.67%-12.63%-45.06%-18.13%-40.02%-61.69%36.74%23.51%60.54%-16.19%-35.61%89.66%-95.24%-
D&A (Non-Cash Add-back)163K83K27K111K114K91K93K89K22K27K24K19K12K26K43K602K338K457K220K2.34M3.18M2.67M
EBIT-173.64M-105.43M-82.26M-5.34M-9.93M-19.32M-9.74M-5.64M-7.96M-18.55M-16.44M-11.45M-9.69M-6.94M-4.32M-5.36M-8.41M-11.23M-19.25M-12.2M-132.19M-70.33M
Net Interest Income30.52M16.63M4.39M1.96M675K0-9K-7K00169K14K7K5K-1K-3K755K32K62K6.59M7.8M1.43M
Interest Income30.52M16.63M5.86M1.96M675K00000169K14K7K5K2K2K763K217K240K6.69M8.38M2.43M
Interest Expense001.47M0009K7K0000003K5K8K185K178K103K588K1M
Other Income/Expense30.53M16.62M4.4M1.96M-85K13K19K165K154K161K169K10K4K1K-1K2M755K11.43M62K4.25M7.8M1.43M
Pretax Income-152.57M-105.43M-83.72M-5.34M-9.93M-19.32M-9.75M-5.65M-7.96M-18.55M-16.44M-11.45M-9.69M-6.94M-4.32M-5.36M-8.42M-11.42M-19.43M-12.3M-132.78M-71.61M
Pretax Margin %--------------------26.25%-3415.05%-13139.63%
Income Tax000000-9K-167K-31K-61K0000000-2.28M0000
Effective Tax Rate %0%0%0%0%0%0%0.09%2.96%0.39%0.33%0%0%0%0%0%0%0%19.98%0%0%0%0%
Net Income-152.57M-105.43M-83.72M-5.34M-9.93M-19.32M-9.74M-5.48M-7.93M-18.49M-16.44M-11.45M-9.69M-6.94M-4.32M-5.36M-8.42M-9.14M-19.43M-12.3M-132.78M-71.61M
Net Margin %--------------------26.25%-3415.05%-13139.63%
Net Income Growth %-39.67%-25.93%-1468.16%46.21%48.63%-98.42%-77.64%30.9%57.1%-12.44%-43.68%-18.12%-39.63%-60.62%19.46%36.29%7.86%52.97%-57.96%90.74%-85.41%-
Net Income (Continuing)-152.57M-105.43M-83.72M-5.34M-9.93M-19.32M-9.74M-5.48M-7.93M-18.49M-16.44M-11.45M-9.69M-6.94M-4.32M-5.36M-8.42M-9.14M-19.43M-12.3M-132.78M-71.61M
Discontinued Operations0000000000000000000000
Minority Interest0000000000000000000000
EPS (Diluted)-2.13-2.31-4.99-4.44-8.27-16.68-8.40-49.79-123.73-382.87-390.96-393.12-710.64-1572.48-2933.25-4808.16-8981.28-12882.00-999999.00-41731.00-468115.00-313891.00
EPS Growth %27.19%53.71%-12.39%46.31%50.42%-98.57%83.13%59.76%67.68%2.07%0.55%44.68%54.81%46.39%38.99%46.46%30.28%99.72%-11082.66%91.09%-49.13%-
EPS (Basic)--2.31-4.99-4.44-8.27-16.68-8.40-49.79-123.73-382.87-390.96-393.12-710.64-1572.48-2933.25-4808.16-8981.28-12882.00-999999.00-41731.00-468115.00-313891.00
Diluted Shares Outstanding71.59M45.61M16.79M14.42M14.41M13.9M4.71M110.1K64.11K48.29K41.98K29.12K13.56K5.71K1.47K1.11K9387824294284228
Basic Shares Outstanding71.59M45.61M16.79M14.42M14.41M13.9M4.71M110.1K64.11K48.29K41.98K29.12K13.56K5.71K1.47K1.11K9387824294284228
Dividend Payout Ratio----------------------

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Dilutive financing dependence risk

Pre-Revenue Status Defines Growth Profile

Based on reported figures, ORKA recorded no revenue across the ten quarters provided, so a traditional growth rate cannot be calculated and top-line trajectory is effectively data unavailable for analysis.

The income statement shows zero revenue throughout the supplied history, with the only line items being operating expenses and a small cost of revenue entry in 2025Q4 and 2026Q1-Q3. The absence of revenue means growth investors should focus instead on R&D progression and clinical milestones rather than sales momentum. Any future revenue trajectory remains speculative and warrants further investigation once commercialization timelines become clearer.

Expense Growth Outpacing Any Operating Scale

As reported in financial statements, ORKA's R&D expense climbed from $18.7M in 2024Q2 to $53.7M in 2026Q3, while SG&A rose from $2.8M to $8.4M over the same period, indicating expanding fixed-cost intensity without offsetting income.

Operating loss widened from $21.5M to $62.1M across the window, reflecting spending that scales with clinical activity rather than revenue. Because there is no gross profit base to leverage, the cost structure behaves as pure burn, and the conventional operating leverage framework does not apply. Investors should monitor whether R&D intensity moderates as trials mature or continues to accelerate.

Net Loss Shaped by Non-Cash Compensation

Based on reported figures, stock-based compensation appeared in several quarters, including $9.1M in 2026Q3 and $10.2M in 2025Q3, which may partially account for the gap between operating and net loss trends.

The reported net loss tracks operating loss closely, with net income consistently slightly less negative than operating income in some periods and more negative in others, suggesting non-operating items are modest. Stock-based compensation is a material component of reported expense and may understate the cash cost of retaining scientific talent. Reported EPS of -0.63 in 2026Q3 versus -0.54 in 2025Q4 also reflects share count changes that warrant monitoring for dilution effects.

R&D Dominates a Clinical-Stage Cost Base

According to recent SEC filings, ORKA's R&D line accounts for the overwhelming majority of total operating expense, with $53.7M of R&D against $8.4M of SG&A in the latest quarter, a ratio of roughly 86 percent to 14 percent.

This cost mix is characteristic of a clinical-stage biologics developer advancing ORKA-001 through trials, where patient recruitment and CMC activities drive spending. The SG&A base has grown more slowly than R&D, which may indicate reasonable overhead discipline during the build-out phase. Internal allocation between programs is not transparent in the supplied data, so program-level efficiency cannot be assessed.

Runway Risk Overshadows Clinical Progress

Based on reported figures, the quarterly operating loss of $62.1M in 2026Q3 compares against reported cash of roughly $46.9M, suggesting a funding gap that may require further capital raises before late-stage milestones.

If quarterly burn persists near the latest run rate, the reported cash balance would cover less than one quarter of operating losses, a dynamic that investors should weigh heavily against the pro-forma effects of the ARCA merger and any PIPE proceeds not visible in this snapshot. Dilution risk is therefore the central counter-argument, as financing may occur at valuations that absorb much of the platform premium the market appears to assign. The thesis could be undermined if clinical data slips or financing terms deteriorate.

ORKA — Frequently Asked Questions

Quick answers to the most common questions about buying ORKA stock.

What was Oruka Therapeutics, Inc.'s (ORKA) revenue in 2025?

For fiscal year 2025, Oruka Therapeutics, Inc. (ORKA) reported total revenue of $0.0M. This represents a 100.0% decline compared to $0.5M in 2005.

Is Oruka Therapeutics, Inc. (ORKA) profitable?

Oruka Therapeutics, Inc. (ORKA) reported a net loss of $105.4M for the fiscal year ending 2025.